Market Access | Regulatory Affairs | HEOR | RWE | HTA | Health Economics | Pharma
Disclaimer: This course contains the use of artificial intelligence.
Launch Fast, Lose Billions: Master the Dark Art of Pharma Market Access
What you’ll learn
- Decode payer decision drivers and predict HTA outcomes using proven frameworks..
- Map IRP cascades across countries and prevent significant global price erosion..
- Calculate optimal launch windows that substantially boost lifetime revenue potential..
- Reduce gross-to-net leakage through strategic channel and contract management..
- Design outcome-based MEAs that secure premium pricing while ensuring payer acceptance..
- Build dynamic pricing models using Monte Carlo and scenario planning techniques..
- Anticipate competitive moves using game theory to protect market positioning..
- Create integrated launch plans that align regulatory, market access, and supply chain..
- Execute a multi-market simulation and benchmark against proven optimal strategies..
- Master tools to defend billions in revenue throughout a drug’s entire lifecycle..
Course Content
- Masterclass 1: The Strategic Imperative: Global P&R Systems & Trends –> 2 lectures • 55min.
- Masterclass 2: The IRP Trap: Managing International Price Referencing –> 2 lectures • 54min.
- Masterclass 3: Launch Sequencing: Choreographing Your Global Rollout –> 2 lectures • 47min.
- Masterclass 4: Gross-to-Net: The Leaky Bucket Problem –> 2 lectures • 50min.
- Masterclass 5: Managed Entry Agreements: From Rebates to Outcomes –> 2 lectures • 55min.
- Capstone Simulation: Build a 5-Market Pricing Strategy –> 2 lectures • 46min.
Requirements
Disclaimer: This course contains the use of artificial intelligence.
Launch Fast, Lose Billions: Master the Dark Art of Pharma Market Access
Every $1 of list price you announce triggers a global chain reaction. A €50,000 price in Italy becomes €8,000 in Brazil within 42 days. A rushed Alzheimer’s launch cost one company $4.2 billion—95% of projected revenue. The problem? You’re optimizing for speed while the market is optimizing for your failure.
This isn’t a course about rebates and paperwork. It’s a strategic weapons system for pricing leaders who refuse to let 40-60% of revenue vanish through PBM black boxes, 340B traps, and IRP cascades.
Across six integrated modules, you’ll deconstruct real-world catastrophes (a $2.3B pricing disaster), reverse-engineer billion-dollar successes (GeneCure’s $1.2M gene therapy MEA), and master the mathematical models that predict payer behavior with 80% accuracy.
What You’ll Build:
- IRP Propagation Models that map how a price change in Portugal ripples to 37 countries
- Launch Sequencing Algorithms that calculate the exact 6-month stabilization window worth $180M
- Gross-to-Net Defense Systems to claw back $20-40M annually from DIR fees and contract pharmacy leakage
- Outcome-Based MEA Contracts that turn “your drug is too expensive” into “we’ll pay $100K if it works”
The capstone simulation throws you into the hot seat: Navigate a Korean competitor ambush, choreograph a 5-market launch, and see your decisions hit real-time P&L. Score yourself against the $418M optimal blueprint.
If you’re done leaving billions on the table, this is your playbook.